Clinical implications of CIP2A protein expression in breast cancer.

The aim of this work is to study the expression and regulatory effects of CIP2A protein in breast cancer and the correlation between CIP2A protein expression and the prognosis of breast cancer. The CIP2A protein level was detected by immunohistochemistry staining. The relationship between CIP2A protein and clinicopathological parameters of breast cancer was determined. It was observed that 448 (35.00 %) of the 1,280 cases positively expressed CIP2A protein. Univariate analysis indicated that CIP2A expression was related to histological grade, lymph node metastasis, distant metastasis, and triple-negative breast cancer (P = 0.001, 0.001, 0.001, and 0.001, respectively). Spearman correlation analysis showed that CIP2A expression has line correlation with histological grade, lymph node metastasis, distant metastasis, triple-negative breast cancer, and TNM stage (P = 0.03, 0.001, 0.008, 0.001, and 0.001, respectively). After multivariate analysis, tumor size, histological grade, lymph node metastasis, triple-negative breast cancer, distant metastasis, and TNM stage were related to CIP2A expression (P = 0.035, 0.001, 0.028, 0.001, 0.001, and 0.001, respectively). CIP2A expression also significantly related to chemotherapeutic sensitivity of breast cancer in the neoadjuvant chemotherapy. In the Cox regression test, histological grade, lymph node metastasis, triple-negative breast cancer, and TNM stage were detected as the independent prognostic factors (P = 0.001, 0.006, 0.01, 0.011, and 0.001, respectively). CIP2A expression may be a potential biomarker for chemotherapeutic sensitivity and prognosis of breast cancer.